AstraZeneca Egypt has announced its collaboration with the Ministry of Health and Population to inaugurate a campaign focused on the early detection and treatment of hepatocellular carcinoma (HCC), one of the most common types of primary liver cancer in Egypt.
The campaign’s primary objective is to increase public awareness regarding the criticality of early liver cancer detection, thereby enhancing recovery rates. This initiative leverages cutting-edge AI technologies and the dissemination of state-of-the-art treatment modalities for liver cancer.
Additionally, the campaign seeks to enhance the proficiency of the Ministry’s medical teams, augmenting the calibre of healthcare extended to patients. This initiative aspires to build a health-conscious society and achieve the Sustainable Development Goals in Egypt Vision 2030.
This announcement was made during a press conference today at the Waldorf Astoria Hotel, coinciding with the signing of an MoU between the Ministry of Health and Population and AstraZeneca Egypt.
The conference was attended by Dr. Khaled Abdel Ghaffar, Minister of Health and Population, H.E. the British Ambassador, Gareth Bayley, and Mr. David Fredrickson, Executive Vice-President, Oncology Business Unit, at AstraZeneca.
The MoU was signed by Dr. Mohamed Hassany, Assistant Minister of Health and Population for Public Health Initiatives, and Dr. Hatem Werdany, Country President Egypt, AstraZeneca.
This two-year MoU encompasses a comprehensive awareness campaign, spanning both field activities and social media, intending to educate more than 30 million citizens about the disease, emphasizing the importance of early diagnosis for liver cancer patients. Additionally, the initiative will inaugurate a specialized training program for medical teams in collaboration with various international cancer centres.
This collaboration reflects AstraZeneca Egypt’s strategic commitment to reinforce Egypt’s healthcare program, given the substantial impact of liver cancer on the population, with over 27,000 new cases diagnosed annually and the unfortunate loss of over 26,000 patients each year.
Consequently, the campaign represents a pivotal initiative within the program to eradicate the hepatitis C virus (HCV), under the auspices of H.E. President Abdel Fattah El-Sisi, as HCV stands as a primary factor linked to hepatocellular carcinoma (HCC), the predominant form of liver cancer.
This collaboration will incorporate advanced AI technology, facilitated by the global firm CliniThink, to analyze patients’ medical data and develop optimal treatment protocols. Furthermore, it introduces cutting-edge international methodologies for early diagnosis and detection of liver diseases, particularly liver cancer, aiming to enhance patient response rates to treatment.
This initiative aligns with the “100 Million Health” initiative launched in 2018, which has significantly contributed to delivering healthcare services to all Egyptian citizens, particularly the most vulnerable segments of society.
